TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Dbv Technologies
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

DBV Technologies completed the last patient visit in its Phase 3 VITESSE clinical trial for a peanut allergy patch targeting children aged 4-7 years. The company expects to release topline data in Q4 2025 and remains committed to developing a non-invasive food allergy treatment.

Insights
DBVT   positive

Company has completed a significant milestone in its clinical trial, showing progress towards potential treatment for peanut allergies in children